IGBMA: Ingrid Schwarzenberger
Head of global regulatory affairs at Sandoz Biopharmaceuticals Ingrid Schwarzenberger, has been appointed chair of the International Generic and Biosimilar Medicines Association (IGBMA) Biosimilars Committee.
Schwarzenberger, who has 15 years of experience at the Biosimilar Medicines Group, said her new role will require close working relationships with regulatory bodies.
“We will continue to closely work with the World Health Organization (WHO) and national/EU regulatory agencies to ensure that WHO standards are implemented around the world and to support regulatory capacity building for the new WHO prequalification procedure pilot project”, said Schwarzenberger.
“Implementing worldwide labelling policies, like in the EU and the US, which reflect the scientific biosimilarity concept, and fine-tuning regulatory frameworks which allow true global development, are new milestones to achieve”, she added.
The IGBA aims to strengthen cooperation between generic medicines manufacturers and their representatives.
IGBA members and associate members include Medicines for Europe, the CGPA (Canada), the AAM (USA), the JAPM (Japan), (GBMA) Australia, ProGenericos (Brazil) and AMEGI (Mexico).
